JP2016507493A - 神経障害及び疼痛のｅｇｆｒ標的治療 - Google Patents

神経障害及び疼痛のｅｇｆｒ標的治療 Download PDF

Info

Publication number
JP2016507493A
JP2016507493A JP2015548291A JP2015548291A JP2016507493A JP 2016507493 A JP2016507493 A JP 2016507493A JP 2015548291 A JP2015548291 A JP 2015548291A JP 2015548291 A JP2015548291 A JP 2015548291A JP 2016507493 A JP2016507493 A JP 2016507493A
Authority
JP
Japan
Prior art keywords
pain
neuropathic pain
egfr
administration
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015548291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507493A5 (cg-RX-API-DMAC7.html
Inventor
クリスティアン ケルステン
クリスティアン ケルステン
マルテ グロンリー キャメロン
マルテ グロンリー キャメロン
スヴェイン ミャランド
スヴェイン ミャランド
Original Assignee
スィーケフス ソールラン ホーエフ
スィーケフス ソールラン ホーエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スィーケフス ソールラン ホーエフ, スィーケフス ソールラン ホーエフ filed Critical スィーケフス ソールラン ホーエフ
Publication of JP2016507493A publication Critical patent/JP2016507493A/ja
Publication of JP2016507493A5 publication Critical patent/JP2016507493A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015548291A 2012-12-21 2013-12-20 神経障害及び疼痛のｅｇｆｒ標的治療 Pending JP2016507493A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740876P 2012-12-21 2012-12-21
US61/740,876 2012-12-21
PCT/EP2013/003931 WO2014095088A1 (en) 2012-12-21 2013-12-20 Egfr targeted therapy of neurological disorders and pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018197322A Division JP2019023227A (ja) 2012-12-21 2018-10-19 神経障害及び疼痛のｅｇｆｒ標的治療

Publications (2)

Publication Number Publication Date
JP2016507493A true JP2016507493A (ja) 2016-03-10
JP2016507493A5 JP2016507493A5 (cg-RX-API-DMAC7.html) 2017-02-09

Family

ID=50002662

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015548291A Pending JP2016507493A (ja) 2012-12-21 2013-12-20 神経障害及び疼痛のｅｇｆｒ標的治療
JP2018197322A Pending JP2019023227A (ja) 2012-12-21 2018-10-19 神経障害及び疼痛のｅｇｆｒ標的治療
JP2022006083A Pending JP2022058654A (ja) 2012-12-21 2022-01-19 神経障害及び疼痛のｅｇｆｒ標的治療
JP2024026738A Pending JP2024069254A (ja) 2012-12-21 2024-02-26 神経障害及び疼痛のｅｇｆｒ標的治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018197322A Pending JP2019023227A (ja) 2012-12-21 2018-10-19 神経障害及び疼痛のｅｇｆｒ標的治療
JP2022006083A Pending JP2022058654A (ja) 2012-12-21 2022-01-19 神経障害及び疼痛のｅｇｆｒ標的治療
JP2024026738A Pending JP2024069254A (ja) 2012-12-21 2024-02-26 神経障害及び疼痛のｅｇｆｒ標的治療

Country Status (13)

Country Link
US (4) US20150320861A1 (cg-RX-API-DMAC7.html)
EP (1) EP2935333A1 (cg-RX-API-DMAC7.html)
JP (4) JP2016507493A (cg-RX-API-DMAC7.html)
KR (1) KR102228358B1 (cg-RX-API-DMAC7.html)
CN (1) CN104968680A (cg-RX-API-DMAC7.html)
AU (1) AU2013362134B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013849A2 (cg-RX-API-DMAC7.html)
CA (1) CA2891855A1 (cg-RX-API-DMAC7.html)
EA (1) EA037709B1 (cg-RX-API-DMAC7.html)
IL (1) IL239542B (cg-RX-API-DMAC7.html)
MX (1) MX376166B (cg-RX-API-DMAC7.html)
WO (1) WO2014095088A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503579B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521253A (ja) * 2018-05-03 2021-08-26 セントロ デ インベスティガシオン イ デサロージョ デ メディカメントス（シデム） パラセタモール：アミトリプチリンの固定用量組成物および混合型がん性疼痛を治療するための方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322414B1 (en) 2015-07-16 2020-09-30 Xomics Biopharma, Inc. Selective oct2 inhibitors for use in preventing toxicity of platinum drugs
US20180140586A1 (en) * 2016-11-22 2018-05-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
WO2020115108A1 (en) 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
WO2021191094A1 (en) 2020-03-24 2021-09-30 University Court Of The University Of Edinburgh Erbb-targeted therapies for neuropathic pain
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
KR102536315B1 (ko) * 2020-09-11 2023-05-25 아주대학교산학협력단 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물
TWI859538B (zh) * 2021-05-21 2024-10-21 美商美國禮來大藥廠 靶向表皮調節素(epiregulin)之化合物及方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU665360B2 (en) * 1991-07-05 1996-01-04 Seragen, Inc. Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
JP3344586B2 (ja) 1993-05-28 2002-11-11 セファロン，インコーポレイテッド インドロカルバゾール誘導体を含有する前立腺病理疾患の治療剤
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
EP0787200B1 (en) 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5650407A (en) 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
AU6261696A (en) 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
CA2340682A1 (en) 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
HUP0200073A3 (en) 1998-08-27 2003-12-29 Aventis Pharma Sa Targeted adenovirus vectors for delivery of heterologous genes
AU2001268513A1 (en) 2000-06-17 2002-01-02 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
EP1873259B1 (en) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
JP2005517450A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＲＮＡ干渉媒介性標的発見および標的評価
AU2003283976B2 (en) 2002-09-27 2009-12-10 Cold Spring Harbor Laboratory Cell-based RNA interference and related methods and compositions
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
WO2005038054A1 (en) 2003-10-20 2005-04-28 Zicai Liang METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES
GB0327726D0 (en) 2003-11-28 2003-12-31 Isis Innovation Method
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
CA2591565C (en) 2004-12-17 2014-06-10 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
AU2007309650A1 (en) 2006-02-08 2008-05-02 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
WO2008006369A1 (en) 2006-07-14 2008-01-17 Santaris Pharma A/S Adenosine receptor antagonists
CU23526B6 (es) * 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
EP2076597A2 (en) 2006-10-09 2009-07-08 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
SG195557A1 (en) * 2008-10-22 2013-12-30 Genentech Inc Modulation of axon degeneration
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
RS55088B1 (sr) * 2011-07-06 2016-12-30 Sykehuset Sorlandet Hf Egfr ciljana terapija

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG, SHYHMIN ET AL.: "Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR A", CANCER RESEARCH, vol. 64, no. 15, JPN7017002809, 2001, pages 5355 - 5362, XP002399541, ISSN: 0003820862, DOI: 10.1158/0008-5472.CAN-04-0562 *
KERSTEN, CHRISTIAN ET AL.: "Cetuximab alleviates neuropathic pain despite tumour progression", BMJ CASE REPORTS, JPN7017002808, 2012, pages 1 - 6, XP009164568, ISSN: 0003820861, DOI: 10.1136/bcr.12.2011.5374 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521253A (ja) * 2018-05-03 2021-08-26 セントロ デ インベスティガシオン イ デサロージョ デ メディカメントス（シデム） パラセタモール：アミトリプチリンの固定用量組成物および混合型がん性疼痛を治療するための方法

Also Published As

Publication number Publication date
EA037709B1 (ru) 2021-05-13
US20230016235A1 (en) 2023-01-19
US11396548B2 (en) 2022-07-26
EP2935333A1 (en) 2015-10-28
CN104968680A (zh) 2015-10-07
WO2014095088A1 (en) 2014-06-26
US20150320861A1 (en) 2015-11-12
BR112015013849A2 (pt) 2017-07-11
IL239542B (en) 2021-02-28
KR20150096802A (ko) 2015-08-25
JP2022058654A (ja) 2022-04-12
AU2013362134A1 (en) 2015-06-11
MX376166B (es) 2025-03-07
AU2013362134B2 (en) 2018-07-05
CA2891855A1 (en) 2014-06-26
ZA201503579B (en) 2016-06-29
JP2019023227A (ja) 2019-02-14
KR102228358B1 (ko) 2021-03-16
US20170073419A1 (en) 2017-03-16
EA201500670A1 (ru) 2016-02-29
IL239542A0 (en) 2015-08-31
MX2015007719A (es) 2015-09-07
US10611844B2 (en) 2020-04-07
US20200216547A1 (en) 2020-07-09
JP2024069254A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
JP2022058654A (ja) 神経障害及び疼痛のｅｇｆｒ標的治療
Mendelsohn The epidermal growth factor receptor as a target for cancer therapy.
AU2012257727B2 (en) Method for EGFR directed combination treatment of cancer
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
JP2024026630A (ja) 神経障害性疼痛の治療用薬剤
Bastholt et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
WO2011090005A1 (ja) 大腸癌の治療用医薬および治療方法
CN107949401A (zh) 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物
Taylor et al. RARE-04. IMPACT OF LIVE, VIRTUAL EDUCATIONAL SYMPOSIA ON PEDIATRIC NEURO-ONCOLOGIST, NEURO-ONCOLOGIST, AND NEUROSURGEON CONFIDENCE, KNOWLEDGE, AND INTENTION TO EMPLOY TARGETED MEDICAL THERAPIES FOR THEIR PATIENTS WITH NEUROFIBROMATOSIS TYPE 1
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK1190637B (en) Method for egfr directed combination treatment of cancer
HK1190637A (en) Method for egfr directed combination treatment of cancer
NZ616183B2 (en) Method for egfr directed combination treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180620